Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

Summary

This is an open-label, dose escalation Phase I study to evaluate the tolerability and efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients with hematologic malignancies after allogeneic stem cell transplantation. Approximately 29 patients will be enrolled, where about 6-12 patients will be included on the dose escalation phase and 20 patients will be on the expansion cohort at maximal tolerated dose.

Timeline

Start

2017-03-20

Primary completion

2019-02-06

Completion

2020-06-22

Outcome

Outcome not reported

Stopped (Enrollment): “Study stopped early due to slow accrual and safety concerns.”

Drugs

Indications